Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.
Trial record 1 of 1 for:    Evaluation of QDOT MICRO™ catheter for pulmonary vein isolation (PVI) in subjects with Paroxysmal atrial Fibrillation (PAF)
Previous Study | Return to List | Next Study

Evaluation of QDOT MICRO™ Catheter for Pulmonary Vein Isolation in Subjects With Paroxysmal Atrial Fibrillation (Q-FFECIENCY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03775512
Recruitment Status : Active, not recruiting
First Posted : December 14, 2018
Last Update Posted : October 16, 2019
Information provided by (Responsible Party):
Biosense Webster, Inc.

Brief Summary:
Prospective, non-randomized, pre-market clinical evaluation of the QDOT MICRO™ Catheter to demonstrate the safety and effectiveness when compared to an historical control performance goal.

Condition or disease Intervention/treatment Phase
Paroxysmal Atrial Fibrillation Device: RF Ablation with QDOT Micro Phase 3

Detailed Description:

Prospective, non-randomized, pre-market clinical evaluation of the QDOT MICRO™ Catheter to demonstrate the safety and effectiveness when compared to an historical control performance goal.

The trial will enroll 185 subjects who are candidates for catheter ablation.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 185 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of QDOT MICRO™ Catheter for Pulmonary Vein Isolation (PVI) in Subjects With PAF
Actual Study Start Date : January 30, 2019
Estimated Primary Completion Date : December 25, 2019
Estimated Study Completion Date : October 30, 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: QDOT Micro
Subjects will be ablated with the QDOT Micro Catheter for Pulmonary Vein Isolation
Device: RF Ablation with QDOT Micro
Subjects will be ablated using QDOT Micro catheter

Primary Outcome Measures :
  1. Acute Safety: Incidence of early onset PAEs [ Time Frame: 7 days of the procedure ]

    Incidence of early onset primary adverse events (PAE) related to the device or procedure. Occurrence of Primary AEs within 7 days of an ablation procedure.

    Primary adverse events include the following conditions

    • Death
    • Atrio-esophageal fistula
    • Cardiac Tamponade/Perforation
    • Myocardial infarction (MI)
    • Stroke / Cerebrovascular accident (CVA)
    • Thromboembolism
    • Transient Ischemic Attack
    • Phrenic Nerve Injury/Diaphragmatic paralysis
    • Heart block
    • PV stenosis
    • Pulmonary edema (Respiratory Insufficiency)
    • Vagal Nerve Injury
    • Pericarditis
    • Major vascular access complication / bleeding

  2. Freedom from atrial tachyarrhythmias recurrence [ Time Frame: 3- 12 months ]
    The primary effectiveness endpoint is defined as the freedom from documented atrial fibrillation, atrial flutter and atrial tachycardia recurrence.

Secondary Outcome Measures :
  1. Incidence of Unanticipated Adverse Device Effects (UADEs) [ Time Frame: 12 months ]
    Incidence of Unanticipated Adverse Device Effects (UADEs)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Symptomatic paroxysmal AF with one electrocardiographically documented AF episode within 6 months prior to enrollment and a a physician's note indicating recurrent self-terminating AF within 7 days . Documentation may include electrocardiogram (ECG); Transtelephonic monitoring (TTM), Holter monitor or telemetry strip.
  • Failed at least one Class I or Class III antiarrhythmic drug as evidenced by recurrent symptomatic AF, contraindicated, or intolerable to the AAD.
  • Age 18 years or older.

Key Exclusion Criteria:

  • Previous surgical or catheter ablation for atrial fibrillation.
  • AF secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause.
  • Previously diagnosed with persistent or long-standing persistent AF and/or Continuous AF > 7 days.
  • Valve repair or replacement or presence of a prosthetic valve.
  • CABG surgery within the past 6 months (180 days).
  • Any carotid stenting or endarterectomy within the past 6 months.
  • Coronary artery bypass grafting, cardiac surgery, or valvular cardiac surgical procedure within the past 6 months.
  • Documented left atrium (LA) thrombus within 1 day prior to the index procedure.
  • Documented LA size > 50 mm.
  • Documented LVEF < 40%.
  • Contraindication to anticoagulation (e.g., heparin).
  • MI/PCI within the past 2 months.
  • Documented thromboembolic event (including transient ischemic attack) within the past 12 months.
  • Uncontrolled heart failure or New York Heart Association (NYHA) function class III or IV.
  • Awaiting cardiac transplantation or other cardiac surgery within the next 12 months.
  • Presence of implanted pacemaker or implantable cardioverter defibrillator (ICD).
  • Women who are pregnant, lactating, or who are of child bearing age and plan on becoming pregnant during the course of the clinical investigation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03775512

Layout table for location information
United States, New York
NYU Langone
New York, New York, United States, 10016
Sponsors and Collaborators
Biosense Webster, Inc.
Layout table for investigator information
Principal Investigator: Emile Daoud Ohio State University
Principal Investigator: Jose Osorio Grandview Medical Center
Principal Investigator: Francis Marchlinksi Hospital of University of Pennsylvania
Principal Investigator: Michael Cutler Intermountain Medical Center
Principal Investigator: Andrea Natale Texas Cardiac Arrhythmia Research Foundation
Principal Investigator: Daniel Melby Abbott Northwestern
Principal Investigator: Miguel Valderabanno Houston Methodist
Principal Investigator: George Monir Florida Hospital
Principal Investigator: Craig Delaughter Texas Heart Health and Vascular
Principal Investigator: Christopher Liu New York Presbyterian Hospital
Principal Investigator: Saumil Oza St. Vincent's Healthcare
Principal Investigator: Ayman Hussein The Cleveland Clinic
Principal Investigator: Robert Fishel JFK Hospital
Principal Investigator: Kenneth Ellenbogen VCU
Principal Investigator: Gery Tomassoni Baptist Hospital
Principal Investigator: Tristram Bahnson Duke University
Principal Investigator: Chris Ellis VUMC
Principal Investigator: Emerson Liu Allegheny College
Principal Investigator: David Wilber Loyola University
Principal Investigator: Moussa Mansour Mass General Hospital
Principal Investigator: Srinivas Dukkipati Icahn School of Medicine at Mount Sinai
Principal Investigator: Hugh McElderry University of Alabama at Birmingham
Principal Investigator: Patrick Hranitzky Wakemed Heart and Vascular

Layout table for additonal information
Responsible Party: Biosense Webster, Inc. Identifier: NCT03775512    
Other Study ID Numbers: BWI_2017_07
First Posted: December 14, 2018    Key Record Dates
Last Update Posted: October 16, 2019
Last Verified: October 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes